JP2024520767A - Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン - Google Patents

Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン Download PDF

Info

Publication number
JP2024520767A
JP2024520767A JP2023575452A JP2023575452A JP2024520767A JP 2024520767 A JP2024520767 A JP 2024520767A JP 2023575452 A JP2023575452 A JP 2023575452A JP 2023575452 A JP2023575452 A JP 2023575452A JP 2024520767 A JP2024520767 A JP 2024520767A
Authority
JP
Japan
Prior art keywords
salt
lidocaine
articaine
covid
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023575452A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024520767A5 (cg-RX-API-DMAC7.html
Inventor
オーストワウダー，クルネリス・ヤン
カンハイ，ロベルト・チャンダープレカシュ・ジャイクリシナ
Original Assignee
スティヒティング・メディシュ・クリニーク・フェルゼン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スティヒティング・メディシュ・クリニーク・フェルゼン filed Critical スティヒティング・メディシュ・クリニーク・フェルゼン
Publication of JP2024520767A publication Critical patent/JP2024520767A/ja
Publication of JP2024520767A5 publication Critical patent/JP2024520767A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023575452A 2021-06-03 2022-06-01 Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン Pending JP2024520767A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2107966.0A GB2607584B (en) 2021-06-03 2021-06-03 Composition and method of treatment
GB2107966.0 2021-06-03
PCT/IB2022/055134 WO2022254363A1 (en) 2021-06-03 2022-06-01 Lidocaine or articaine for treating covid-19, autoimmune disease or cytokine storm response

Publications (2)

Publication Number Publication Date
JP2024520767A true JP2024520767A (ja) 2024-05-24
JP2024520767A5 JP2024520767A5 (cg-RX-API-DMAC7.html) 2025-06-02

Family

ID=76838703

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023575452A Pending JP2024520767A (ja) 2021-06-03 2022-06-01 Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン

Country Status (6)

Country Link
US (1) US20240269109A1 (cg-RX-API-DMAC7.html)
EP (1) EP4346791A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520767A (cg-RX-API-DMAC7.html)
CN (1) CN117715633A (cg-RX-API-DMAC7.html)
GB (1) GB2607584B (cg-RX-API-DMAC7.html)
WO (1) WO2022254363A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2639834A (en) * 2024-03-22 2025-10-08 Remicine Ip B V Composition and method of treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072923A1 (ja) * 2005-12-22 2007-06-28 Kowa Company, Ltd. ステロイドの経時的安定性が改善された外用製剤
JP2014043449A (ja) * 2008-03-06 2014-03-13 Halozyme Inc 可活性化型マトリックス分解酵素の生体内一時的制御
CN106692120A (zh) * 2016-12-15 2017-05-24 刘力 利多卡因的药物组合物及其用途
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994008550A1 (en) * 1992-10-09 1994-04-28 The Procter & Gamble Company Anaesthetic compositions
TWI464148B (zh) * 2006-03-16 2014-12-11 Evotec Us Inc 作為ｐ２ｘ7調節劑之雙環雜芳基化合物與其用途
CN103142643B (zh) * 2013-03-22 2014-07-02 新疆医科大学第一附属医院 Alha心脏停搏液及其制备方法
CN104127397B (zh) * 2014-08-19 2016-04-27 董颖颖 一种治疗急慢性过敏性及充血性皮肤病的药物及方法
CN111150738A (zh) * 2020-02-06 2020-05-15 西安交通大学医学院第二附属医院 一种治疗皮肤病的外用药物
CA3178140A1 (en) * 2020-03-31 2021-10-07 Nomoreitis B.V. Treatment of hyperinflammatory syndrome

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007072923A1 (ja) * 2005-12-22 2007-06-28 Kowa Company, Ltd. ステロイドの経時的安定性が改善された外用製剤
JP2014043449A (ja) * 2008-03-06 2014-03-13 Halozyme Inc 可活性化型マトリックス分解酵素の生体内一時的制御
CN106692120A (zh) * 2016-12-15 2017-05-24 刘力 利多卡因的药物组合物及其用途
RU2742505C1 (ru) * 2020-10-01 2021-02-08 Общество с ограниченной ответственностью "Институт термологии" Аэрозоль для инвазивной механической вентиляции легких при covid-19

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"リドカインポンプスプレー８％「日新」", 医薬品インタビューフォーム, vol. 第３版, JPN6026001374, January 2015 (2015-01-01), ISSN: 0005773429 *
HASSANE SADOU YAYE ET. AL.: "Management of diabetic foot ulcers: a 25% lidocaine topical cream formulation design, physicochemica", EUR J HOSP PHARM, vol. 27, JPN6026001371, 2020, pages 162 - 167, ISSN: 0005773431 *
JAMES P. ORLOWSKI: "EMERGENCY ALTERNATIVES TO INTRAVENOUS ACCESS", PEDIATRIC CLINICS OF NORTH AMERICA, vol. 41 (6), JPN6026001370, 1994, pages 1183 - 1199, ISSN: 0005773430 *
KAHORU NISHINA ET. AL.: "Intervenous Lidocaine Attenuates Acute Lung Injury Induced by Hydrochloric Acid Aspiration in Rabbit", ANESTHESIOLOGY, vol. 88, JPN6026001369, 1998, pages 1300 - 1309, ISSN: 0005773428 *
T.K. HUANG ET. AL.: "Surfactant Lavage with Lidocane Improves Pulmonary Function in Piglets after HCl-Induced Acute Lung", LUNG, vol. 182 (1), JPN6026001372, 2004, pages 15 - 25, ISSN: 0005773432 *
WILLIAM M. CHINN ET. AL.: "Plasma Levels of Lidocaine Following Nebulized Aerosol Administration", CHEST, vol. 71 (3), JPN6026001373, 1977, pages 346 - 348, ISSN: 0005773433 *
Y. TAKAO ET. AL.: "Lidocaine attenuates hyperoxic lung injury in rabbits", ACTA ANAESTHESIOL SCAND, vol. 40, JPN6026001368, 1996, pages 318 - 325, ISSN: 0005773427 *
ZIAD A. ALI ET. AL.: "Nubulized Lidocaine in COVID-19, An Hypothesis", MEDICAL HYPOTHESES, vol. 144, JPN6026001367, 2020, pages 109947, ISSN: 0005773426 *

Also Published As

Publication number Publication date
GB2607584A (en) 2022-12-14
CN117715633A (zh) 2024-03-15
EP4346791A1 (en) 2024-04-10
GB202107966D0 (en) 2021-07-21
US20240269109A1 (en) 2024-08-15
GB2607584B (en) 2024-07-17
WO2022254363A1 (en) 2022-12-08

Similar Documents

Publication Publication Date Title
ES2319667T3 (es) Composiciones farmaceuticas que contienen midazolam en una concentracion elevada.
KR100810872B1 (ko) 감기 치료용 조성물
RU2255736C2 (ru) Фармацевтические композиции, содержащие золмитриптан
ES2383433T3 (es) Formulación farmacéutica de apomorfina para administración bucal
CN108135889A (zh) 用于在危重监护治疗期间使用的镇静方法和肠胃外制剂
ES2935684T3 (es) Formulaciones de epinefrina intranasales y métodos para el tratamiento de enfermedades
ES2738652T3 (es) Composiciones de midazolam para administración bucal en el tratamiento de convulsiones para obtener comienzo de acción rápido
US20150352038A1 (en) A dosage form for administering an active principle for accelerated sleep induction and/or for treating sleep disorders and/or for treating a central nervous system disorder
KR20220081311A (ko) 니클로사마이드를 포함하는 근육내 및/또는 피하 투여용 약학적 조성물
JP2024520767A (ja) Ｃｏｖｉｄ－１９、自己免疫疾患、又はサイトカインストーム応答を処置するためのリドカイン又はアルチカイン
ES2894330T3 (es) Acido acetilsalicílico para uso en el tratamiento de la influenza de moderada a grave
JP5811404B2 (ja) セトロンを頬側経粘膜投与するための処方物（ｆｏｒｍｕｌａｔｉｏｎ）
US11497747B2 (en) Compositions and methods for treating lung injuries associated with SARS-CoV-2 infections
ES2938574T3 (es) Péptido para la prevención o el tratamiento de la COVID-19
BRPI1015515A2 (pt) Método para diminuir a vontade de fumar, que não produz irritação
KR20180030399A (ko) 네뷸라이저용 조성물
JP2024532288A (ja) 抗プリン作動薬を用いて神経系障害を処置するための方法
CA3213365A1 (en) Prevention and treatment of coronavirus infection
US20100063251A1 (en) Compositions and methods for treatment of chronic fatigue syndrome and neurodegenerative diseases
ol Occurrence MGRANAL
CN110545809A (zh) 治疗发作性疾病的方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260119

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260415